Description of Invention: This technology provides a clonally derived macula densa cell line (MMDD1 cells) that closely mimics the known molecular expression pattern of native macula densa (MD) cells. MMDD1 cells are developed from SV-40 transgenic mice using fluorescence-activated cell sorting of renal tubular cells labeled with segment-specific fluorescent lectins. The MMDD1 cells of this technology express COX-2, bNOS, NKCC2, and ROMK, but not Tamm-Horsfall protein, and show rapid 86Rb+ uptake that is inhibited by a reduction in NaCl concentration and by bumetanide or furosemide. These MMDD1 cells provide a useful in vitro model for the study of Macula Densa function.
Research Tool -- patent protection is not being pursued for this technology
Relevant Publication:
T Yang, JM Park, L Arend, Y Huang, R Topaloglu, A Pasumarthy, H Praetorius, K Spring, JP Briggs, J Schnermann. Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem. 2000 Dec 1;275(48):37922-37929. [ PubMed: 10982805 ]
Licensing Status: Available for licensing under a Biological Materials License Agreement.
Collaborative Research Opportunity: The National Institute of Diabetes and Digestive and Kidney Diseases Kidney Disease Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the clonally derived macula densa cell line (MMDD1 cells). Please contact Cindy Fuchs at 301-451-3636 for more information.
Portfolios: Devices/Instrumentation Devices/Instrumentation - Research Tools and Materials Internal Medicine Internal Medicine - Research Materials Research Materials
For Additional Information Please Contact: Suryanarayana Vepa Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: vepas@mail.nih.gov Phone: 301-435-5020 Fax: 301-402-0220
Description of Invention:
This technology provides a clonally derived macula densa cell line (MMDD1 cells) that closely mimics the known molecular expression pattern of native macula densa (MD) cells. MMDD1 cells are developed from SV-40 transgenic mice using fluorescence-activated cell sorting of renal tubular cells labeled with segment-specific fluorescent lectins. The MMDD1 cells of this technology express COX-2, bNOS, NKCC2, and ROMK, but not Tamm-Horsfall protein, and show rapid 86Rb+ uptake that is inhibited by a reduction in NaCl concentration and by bumetanide or furosemide. These MMDD1 cells provide a useful in vitro model for the study of Macula Densa function.
Inventors:
Jurgen B Schnermann (NIDDK)
Patent Status:
HHS, Reference No. E-234-2009/0
Research Tool -- patent protection is not being pursued for this technology
Relevant Publication:
Licensing Status:
Available for licensing under a Biological Materials License Agreement.
Collaborative Research Opportunity:
The National Institute of Diabetes and Digestive and Kidney Diseases Kidney Disease Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the clonally derived macula densa cell line (MMDD1 cells). Please contact Cindy Fuchs at 301-451-3636 for more information.
Portfolios:
Devices/Instrumentation
Devices/Instrumentation - Research Tools and Materials
Internal Medicine
Internal Medicine - Research Materials
Research Materials
For Additional Information Please Contact:
Suryanarayana Vepa Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vepas@mail.nih.gov
Phone: 301-435-5020
Fax: 301-402-0220
Ref No: 2062
Updated: 01/2010